Oral osmotic device with hydrogel driving member

• US 5,573,776 A
• Filed: 09/08/1994
• Issued: 11/12/1996
• Est. Priority Date: 12/02/1992
• Status: Expired due to Term

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Place, Virgil A., Barclay, Brian L., Wright, Jeri D., Childers, Jerry D., Harrison, Juan M. E., Wong, Patrick S.
• Primary Examiner(s): VENKAT, JYOTHSNA A
• Application Number:
  US08/303,288
• Time in Patent Office: 796 Days
• Field of Search: 424/434, 424/435, 424/468, 424/473
• US Class Current: 424/435
• CPC Class Codes: A61K 31/48 Ergoline derivatives, e.g. lysergic acid, ergotamine
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Abstract

An osmotic device (10) for delivering an ergot alkaloid into the mouth of a human patient is disclosed. The device (10) has a size and shape adapting it to be comfortably retained in the mouth for extended periods of time. The device (10) comprises a wall (12) surrounding a compartment (13) housing a layer of an ergot alkaloid (14) and a layer (16) of a fluid swellable, hydrophilic polymer. A passageway (17) in the wall (12) connects the ergot alkaloid (14) with the exterior of the device (10). The wall (12) is permeable to the passage of aqueous biological fluid but substantially impermeable to the passage of the hydrophilic polymer (16). In one embodiment the ergot alkaloid (14) has a different color than the hydrophilic polymer (16). The wall (12) is sufficiently translucent to permit the patient to see the amount of ergot alkaloid (14) remaining to be delivered. Marking lines (19) may be provided on the wall (12) indicating the amount of ergot alkaloid (14) which has been delivered and/or the amount remaining to be delivered.

Claims

1. An osmotic device for the controlled delivery of an ergot alkaloid to a mouth of an animal over an extended delivery period, the device comprising:

a wall sized and shaped for comfortably retaining the device in the oral cavity for the extended delivery period, wherein the size and shape for comfortably retaining the device in the oral cavity over the extended delivery period includes a smooth oval shape with an aspect ratio in the range of about 1.2;

1 to about 3;

1, a height of about 0.5 to about 10 mm, and a volume of less than about 2 cm³, the wall surrounding and forming a compartment containing (i) a layer of a dose of the ergot alkaloid agent and a gelling agent, and (ii) a layer of a hydrophilic polymer, and a passageway in the semipermeable wall communicating with the layer of the ergot alkaloid in the compartment and with the exterior of the device, the wall being formed of a semipermeable material which is (i) permeable to the passage of the aqueous fluid and (ii) impermeable to the passage of the hydrophilic polymer, wherein the device includes a mechanism for visually signaling the animal when the dose of the ergot alkaloid has been delivered from the device.

2. The osmotic device for the controlled delivery of the ergot alkaloid according to claim 1, wherein the mechanism includes providing the layer of the ergot alkaloid with a color which contrasts with the hydrophilic polymer layer, the semipermeable wall being sufficiently translucent to permit visual inspection of the ergot alkaloid present in the compartment.

3. The osmotic device for the controlled delivery of the ergot alkaloid according to claim 2, wherein the ergot alkaloid is a member selected from the group consisting of ergobasine, ergometrine, ergostetrine, ergotamine, ergosine, ergocristine, ergocryptine, ergocornine, ergotaminine, ergosinine, ergocristinine, ergocryptinine, ergocorninine, ergoloids, ergonovine, ergosterol, ergotoxine, ergotinine, combinations thereof and the pharmacologically acceptable salts thereof.

4. The osmotic device for the controlled delivery of the ergot alkaloid according to claim 2, wherein the ergot alkaloid is dihydroergotamine methanesulfonate.

5. The osmotic device for the controlled delivery of the ergot alkaloid according to claim 2, wherein the semipermeable wall has an overcoating containing the ergot alkaloid.

15. The osmotic device for the controlled delivery of the ergot alkaloid according to claim 2, wherein the semipermeable wall comprises 60 wt % cellulose acetate and 40% hydroxypropylcellulose.

16. The osmotic device for the controlled delivery of the ergot alkaloid according to claim 2, wherein the semipermeable wall comprises 60-70% cellulose acetate and 40-30% polyethylene glycol.

6. A method of treating vascular headache which comprises the controlled delivery of an ergot alkaloid, to a mouth of a human over an extended delivery period, comprising:

(a) shaping an osmotic device into a size and shape suitable for comfortably retaining the device in the oral cavity for the extended delivery period, said shape comprising a smooth oval with an aspect ratio in the range of about 1.2;

1 to about 3;

1, a height of about 0.5 to about 10 mm. and a volume of less than about 2 cm³ ;

(b) forming a wall surrounding a compartment containing (i) a layer of a dose of the ergot alkaloid and a gelling agent and (ii) a layer of a hydrophilic polymer;

(c) forming the wall of a semipermeable material which is (i) permeable to the passage of the aqueous fluid and (ii) impermeable to the passage of the hydrophilic polymer;

(d) forming a passageway in the semipermeable wall communicating with the layer of ergot alkaloid in the compartment and with the exterior of the device;

(e) placing the device in the oral cavity of an animal; and

(f) periodically tasting the device to determine when a predetermined dose of the ergot alkaloid has been delivered.

7. The method of treating vascular headache according to claim 6 which includes providing the layer of ergot alkaloid with a taste which contrasts with the hydrophilic polymer layer taste.

9. The method of treating vascular headache according to claim 6, wherein the wall contains a translucent cellulose polymer.

10. The method of treating vascular headache according to claim 6, wherein the semipermeable wall has an overcoating containing the ergot alkaloid.

11. The method of treating vascular headache according to claim 6, wherein the extended delivery period is about 0.5 to about 6 hours.

12. The method of treating vascular headache according to claim 6, wherein the extended delivery period is about 2 to about 4 hours.

13. The method of treating vascular headache according to claim 6, wherein the ergot alkaloid is a member selected from the group consisting of ergobasine, ergometrine, ergostetrine, ergotamine, ergosine, ergocristine, ergocryptine, ergocornine, ergotaminine, ergosinine, ergocristinine, ergocryptinine, ergocorninine, ergoloids, ergonovine, ergosterol, ergotoxine, ergotinine, combinations thereof and the pharmacologically acceptable salts thereof.

14. The method of treating vascular headache according to claim 6, wherein the ergot alkaloid is dihydroergotamine methanesulfonate.

8. A method of treating vascular headache which comprises the controlled delivery of an ergot alkaloid, to a mouth of a human over an extended delivery period, comprising:

(a) shaping an osmotic device with a size and shape suitable for comfortably retaining the device in the oral cavity for the extended delivery period, slid shape comprising a smooth oval With an aspect ratio in the range of about 1.2;

1 to about 3;

1, a height of about 0.5 to about 10 mm. and a volume of less than about 2 cm³ ;

(b) forming a wall surrounding a compartment containing (i) a layer of a dose of the ergot alkaloid and a gelling agent and (ii) a layer of a hydrophilic polymer;

(c) providing the layer of the ergot alkaloid with a color which contrasts with the hydrophilic polymer layer;

(d) forming the wall of a semipermeable material which is (i) permeable to the passage of the aqueous fluid, (ii) impermeable to the passage of the hydrophilic polymer, and sufficiently translucent to permit the visual inspection of the ergot alkaloid present in the compartment;

(e) forming a passageway in the semipermeable wall communicating with the layer of ergot alkaloid in the compartment and with the exterior of the device;

(f) placing the device in the oral cavity of an animal; and

(g) periodically inspecting the device to determine when a predetermined dose of the ergot alkaloid has been delivered.